Evidence map›Paper›PMID 35324982›Full record

ArticlePloS one2022

Polymorphisms in the hypoxia inducible factor binding site of the macrophage migration inhibitory factor gene promoter in schizophrenia.

Satoshi Okazaki, Shuken Boku, Yuichiro Watanabe, Ikuo Otsuka, Tadasu Horai, Ryo Morikawa, Atsushi Kimura, Naofumi Shimmyo, Takaki Tanifuji, Toshiyuki Someya and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Pharmacological modulation of HIF-1 in the treatment of neuropsychiatric disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Satoshi OkazakiDepartment of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan.
Shuken BokuDepartment of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan.ORCID 0000-0003-3089-3201
Yuichiro WatanabeDepartment of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Ikuo OtsukaDepartment of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan.
Tadasu HoraiDepartment of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan.
Ryo MorikawaDepartment of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Atsushi KimuraDepartment of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan.
Naofumi ShimmyoDepartment of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan.
Takaki TanifujiDepartment of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan.
Toshiyuki SomeyaDepartment of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Akitoyo HishimotoDepartment of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan.
Kobe University · JPNiigata University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMacrophage migration inhibitory factor (MIF) is a multifunctional cytokine that promotes neurogenesis and neuroprotection. MIF is predominantly expressed in astrocytes in the brain. The serum MIF level and microsatellites/single nucleotide polymorphisms (SNPs) in the MIF gene promoter region are known to be associated with schizophrenia (SCZ). Interestingly, previous studies reported that hypoxia, an environmental risk factor for SCZ, induced MIF expression through binding of the hypoxia inducible factor (HIF)-1 to the hypoxia response element (HRE) in the MIF promoter.

methodsWe investigated the involvement of MIF in SCZ while focusing on the HIF pathway. First, we conducted an association study of the SNP rs17004038 (C>A) in the HRE of the MIF promoter between 1758 patients with SCZ and 1507 controls. Next, we investigated the effect of hypoxia on MIF expression in primary cultured astrocytes derived from neonatal mice forebrain.

resultsSNP rs17004038 was significantly associated with SCZ (p = 0.0424, odds ratio = 1.445), indicating that this SNP in the HRE of the MIF promoter was a genetic risk factor for SCZ. Hypoxia induced MIF mRNA expression and MIF protein production and increased HIF-1 binding to the MIF promoter, while the activity of the MIF promoter was suppressed by mutations in the HRE and by deletion of the HRE in astrocytes.

conclusionThese results suggest that SNP rs17004038 in the HRE of the MIF promoter was significantly associated with SCZ and may be involved in the pathophysiology of SCZ via suppression of hypoxia and HIF pathway-induced MIF expression.

Indexed as

Macrophage Migration-Inhibitory FactorsSchizophreniaAnimalsBinding SitesHumansHypoxiaHypoxia-Inducible Factor 1, alpha SubunitMicePolymorphism, Single NucleotidePromoter Regions, GeneticHypoxia-Inducible Factor 1, alpha SubunitMacrophage Migration-Inhibitory Factors

Identifiers

PMID35324982
PMCPMC8946738
OpenAlexW4220799303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.